Francis Parnis

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Brian I. Rini, Thomas Powles, Michael B. Atkins et al. · The Lancet · 2019 · 988 citations

Urology, Genitourinary Cancer, Medicine +7

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg et al. · The Lancet · 2021 · 313 citations · Full text

Urology, Oncology, Genitourinary Cancer +6

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium

Ziad Bakouny, Talal El Zarif, Shaan Dudani et al. · European Urology · 2022 · 103 citations · Full text

Surgical Oncology, Upfront Cytoreductive Nephrectomy, Urology +8

Treatment of Invasive Thymoma With Single-Agent Ifosfamide

Martin Highley, Craig Underhill, Francis Parnis et al. · Journal of Clinical Oncology · 1999 · 96 citations